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INCREASED SEVERITY OF SYNOVIAL HYPERTROPHY BY ULTRASOUND
IN KNEE OSTEOARTHRITIS OF SHORTER DISEASE DURATION
N. Navarro, C. Orellana, J. Calvet, M. Garcı´a-Manrique, J. Grataco´s,
M. Larrosa. Hosp. de Sabadell (Parc Taul´ı), Sabadell, Spain
Purpose: To analyze whether the existence or severity of inﬂammatory
changes as detected by ultrasound (synovial effusion and /or
hypertrophy) are related to disease duration in patients with knee
osteoarthritis.
Methods: Patients aged 50 y or more with symptomatic osteoarthritis
of the knee and joint effusion, Kellgren-Lawrence II-III. Demographics,
BMI, duration from onset of symptoms, pain assessed by VAS (0–10 cm)
and the Lequesne index algofuncional were analyzed in a cross-sectional
study. Knee ultrasound was performed evaluating and measuring the
presence of effusion and synovial hypertrophy at the suprapatellar
midline. Two groups were established depending on whether the
evolution time from the onset of symptoms was less than or equal
to or greater than 2 years.
Results: Thirty patients were analyzed, F/M 29/6, age 61.7±9.6 y, disease
duration 46.1±43 months, BMI 30.6±4.9 kg/cm2. Disease duration was
≤ 2 years in 19 patients (54.3%). There were no differences according
to disease duration with regard to age, BMI or radiological grade.
Patients with osteoarthritis of the knee with less evolution time
showed a moderate tendency to have a greater joint effusion (7±3.1
vs. 6.6±2.6mm, ns). Synovial hypertrophy was signiﬁcantly greater in
the shorter duration group (6.9±2.1 vs. 4.1±2.1mm, P< 0.005) and also
showed a tendency to have higher pain by VAS (6.5±1.5 vs. 5.9±2.6, ns).
On the other hand, patients with a longer history of knee OA showed
signiﬁcantly higher scores on the Lequesne index (11.3±4 vs. 8.4±2.6,
p < 0.05).
Conclusions: In this sample of patients with symptomatic knee OA,
synovial hypertrophy had a greater thickness in patients with shorter
disease duration. This ﬁnding could be related to the existence of pain
in the early stages of the disease.
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ASSOCIATION BETWEEN METABOLIC SYNDROME AND SYNOVITIS
IN PATIENTS WITH KNEE OSTEOARTHRITIS
C. Orellana, N. Navarro, I. Va´zquez, M. Moreno, C. Galisteo, J. Grataco´s,
M. Larrosa. Hosp. de Sabadell (Parc Taul´ı), Sabadell, Spain
Purpose: To assess whether patients with knee osteoarthritis and
metabolic syndrome have an increased frequency of inﬂammatory
features as detected by ultrasound.
Methods: Patients aged 50 years or more with symptomatic
osteoarthritis of the knee and joint effusion, Kellgren-Lawrence II-III.
Demographics, BMI, disease duration, pain assessed by VAS (0–10 cm),
algofuncional Lequesne index and the existence of metabolic syndrome
(ATP III criteria) were assessed. Knee ultrasound was performed
evaluating and measuring the presence of effusion and synovial
hypertrophy at the suprapatellar midline.
Results: We analyzed 35 patients, F/M 29/6, age 61.7±9.6 y, disease
duration 46.1±43 months, BMI 30.6±4.9 kg/cm2. Eight patients (22.9%)
met diagnostic criteria for metabolic syndrome. There were no signiﬁcant
differences in age, BMI or radiological grade. Patients with metabolic
syndrome had a higher mean duration (76.6 vs. 37.2 months, p< 0.05).
In patients with metabolic syndrome there was a clear trend, although
not statistically signiﬁcant, to have a more prominent joint effusion
(7.2±2.7 vs. 6.2±3.2mm) and a greater percentage of patients with
signiﬁcant synovial hypertrophy (>4mm) (5/8 (62.5%) vs. 14/27 (51.9%),
while no difference was evident in relation to the average thickness of
the hypertrophy in patients with synovitis in both groups. Patients with
metabolic syndrome had higher pain (VAS 6.2±1.5 vs. 5.8±1.9, ns) and
higher scores on the Lequesne index (12.1±4.5 vs. 9±2.9, p < 0.05).
Conclusions: In this sample of patients with symptomatic knee
osteoarthritis, comorbidity in the form of metabolic syndrome was
associated with greater functional impairment as measured by the
Lequesne index and a nonsigniﬁcant trend (probably related to small
sample size) to show higher prevalence of hypertrophic synovium and
increased synovial effusion.
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ENDOGENOUS PARATHYROID HORMONE IS ASSOCIATED WITH
REDUCED CARTILAGE VOLUME IN VIVO IN A POPULATION-BASED
SAMPLE OF ADULT WOMEN
S. Brennan1, F. Cicuttini1, J. Pasco2, M. Kotowicz3, M. Henry2,
G. Nicholson4, A. Wluka1. 1Monash Univ., Melbourne, Australia; 2Deakin
Univ., Geelong, Australia; 3Barwon Hlth., Geelong, Australia; 4Univ. of
Queensland, St Lucia, Australia
Purpose: Parathyroid hormone(PTH) has complex actions on bone when
administered exogenously, and intermittent injection is anabolic to bone.
Current data suggest that exogenous PTH may exert a positive inﬂuence
upon cartilage after injury. However, little are known about endogenous
PTH and cartilage in vivo, and the role PTH may play in changes to knee
structure, as precursors to the onset or progression of osteoarthritis.
Thus, the aim of this study was to examine the association between
endogenous PTH and cartilage volume in a healthy adult population
without any signs of osteoarthritis.
Methods:Magnetic resonance imaging of the knee was performed on 101
asymptomatic females aged 35–49 years(2007–9). Blood samples(PTH
and vitamin D) were obtained 10 years prior(1994–7), and stored at
−80°C for random batch analyses. Serum intact PTH was quantiﬁed
by chemiluminescent enzyme assay. Serum vitamin D(25[OH]D) was
assayed using an equilibrium radioimmunoassay after extraction with
acetonitrile.
Results: After adjustment for age, BMI and bone area, a 1-unit(pmol/L)
increase in PTH was associated with reduced medial cartilage volume
[regression coefﬁcient ± standard deviation, p value](−0.7±0.3, p = 0.03).
Further adjustment for seasonal variation increased the strength of
association(−0.8±0.3, p = 0.01), however results were similar after further
adjustment for 25[OH]D(−0.08±0.4, p = 0.03). No associations were
observed with lateral cartilage volume (0.2≤p≤0.5). All results remained
signiﬁcant(p < 0.01) after excluding subjects with osteophytes to account
for the possibility of pre-clinical osteoarthritis.
Conclusions: This study suggests greater levels of PTH might be
detrimental to cartilage in vivo in humans. High PTH may reduce
the ability of cartilage to heal following injury, similar to the reduced
healing ability of cartilage observed in animal studies. These data suggest




DEXTROSE PROLOTHERAPY FOR KNEE OSTEOARTHRITIS: RESULTS
OF A RANDOMIZED CONTROLLED TRIAL
D.P. Rabago, D.J. Miller, A.E. Zgierska, M. Mundt, R.X. Kijowski, B. Jessica,
J.J. Patterson. Univ. of Wisconsin Sch. of Med. and Publ. Hlth., Madison, WI,
USA
Purpose: Knee osteoarthritis (KOA) is common, expensive and
debilitating. Sources of pain include the joint capsule, ligaments,
synovium, bone, menisci and extra-articular ligament and tendon
attachments. Prolotherapy is a complementary and alternative injection
therapy for chronic musculoskeletal pain including KOA hypothesized to
stimulate healing of chronically injured tissue. Prolotherapy injections
directly target the multiple pain-generating structures associated with
KOA in and around the knee, but is poorly studied.
Methods: The objective of our study was to assess the efﬁcacy of
prolotherapy for chronic KOA in an NIH-NCCAM funded study. We
conducted a 3-arm (prolotherapy, saline injections, at-home exercise)
randomized controlled trial. The injector, all assessors and injection
group subjects were blind to group allocation. Adult subjects were
recruited from outpatient settings. Inclusion criteria included at least
3 months of symptomatic KOA and clinically determined KOA using
American Rheumatological Association criteria. Blinded injections were
performed at 1, 5, and 9 weeks with as-needed injection sessions at
weeks 13 and 17. Extra-articular injections were done at peri-articular
tendon and ligament insertions. A single intra-articular injection was
performed through an infero-medial approach. Extra- and intra-articular
prolotherapy injections were 15% and 25% dextrose respectively; control
injections were saline. Exercise subjects received an exercise manual and
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in-person instruction on at-home knee exercise. The primary outcome
measure was a composite score on the Western Ontario McMaster
University Osteoarthritis Index (WOMAC; 100 points), which assessed
knee pain, function and stiffness on a per subject basis. The secondary
outcome was the Knee Pain Scale (KPS) which assessed knee pain severity
and frequency on a per knee basis; both were done at baseline, 5, 9
12, 26 and 52 weeks. Procedure-related opioid medication use, subject
satisfaction and adverse events were also assessed.
Results: Analysis was by intention to treat. No signiﬁcant baseline
differences existed between the groups in age, gender, pain duration,
body mass index or WOMAC scores. 89 subjects (57±8.3 years old,
59 female) with moderate to severe KOA received an average of 4.3±0.7
prolotherapy injection sessions over a 17-week treatment period. All
groups reported improved composite WOMAC scores compared to
baseline status (p < 0.01) at 52 weeks. However, WOMAC scores for
prolotherapy subjects, adjusted for gender, age and body mass index
showed signiﬁcantly greater improvement onWOMAC score at 52 weeks;
15.32±3.52 points for prolotherapy compared to 7.68±3.41 points for
saline injection (p < 0.05) and 8.25±3.33 points for exercise (p< 0.05).
The improvement by prolotherapy subjects exceeded minimal clinical
important difference. KPS scores of prolotherapy subjects showed similar
improvement per injected knee compared to baseline status (p < 0.001)
and controls (p < 0.05). Prescribed post-procedure opioid medication
resulted in rapid diminution of prolotherapy injection pain. Satisfaction
with prolotherapy was high and there were no adverse events.
Conclusions: Prolotherapy resulted in safe, signiﬁcant, sustained
improvement of pain, function and stiffness scores compared to blinded
saline injections and at-home exercises in knee osteoarthritis.
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A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY OF rhFGF18 ADMINISTERED INTRAARTICULARLY
USING SINGLE OR MULTIPLE ASCENDING DOSES IN PATIENTS WITH
PRIMARY KNEE OSTEOARTHRITIS (OA), SCHEDULED FOR TOTAL KNEE
REPLACEMENT
L.E. Dahlberg1, K. Flechsenhar2, D. Dreher2, S. Gouteux2, J.S. Jurvelin3.
1Lund Univ., Malmo¨, Sweden; 2Merck Serono S.A. (an afﬁliate of Merck
KGaA, Darmstadt, Germany), Geneva, Switzerland; 3Univ. of Eastern
Finland, Kuopio, Finland
Purpose: No approved disease-modifying OA drugs (DMOAD) are
available. Use of a chondrocyte-targeted growth factor is a promising
approach with the potential to induce chondrocyte proliferation, increase
matrix production and promote cartilage repair. This Phase I study
evaluated the local and systemic acute safety of recombinant human
ﬁbroblast growth factor 18 (rhFGF18) intraarticular (i.a.) injection,
after single ascending dose (SAD) and multiple ascending dose (MAD)
regimens in candidates for total knee replacement (TKR) surgery. As
secondary objectives, effects of rhFGF18 on systemic biomarkers and
exposure were evaluated. Tertiary objectives were to assess: effect of
rhFGF18 on knee cartilage in selected regions of interest by MRI and
X-ray; cartilage structure and absence/presence of cartilage proliferation
from samples taken during TKR surgery; effect of rhFGF18 on OA
symptoms in the target knee. An exploratory objective was to evaluate
biomechanical properties of cartilage taken during TKR surgery.
Methods: Eligible patients were ≥40y with primary femorotibial knee
OA, who were candidates for TKR surgery (planned ≥2 weeks after
anticipated last injection of study drug); stable oral OA treatment was
permitted. Patients received rhFGF18 or placebo, randomized 3:1 per
cohort, injected i.a. into the target knee once (SAD) or once weekly for
3 weeks (MAD). SAD cohorts received 3mg, 10mg, 30mg, 100mg or 300mg;
MAD cohorts received 10mg, 30mg, 100mg, 300mg or highest tolerated
dose. Follow-up and safety reviews occurred before each dose escalation.
All subjects had ﬁnal review 24 weeks after ﬁrst injection. Unconﬁned
compression testing (dynamic and equilibrium modulus) and histological
analysis (modiﬁed Mankin scoring) were conducted for cartilage taken
during TKR surgery.
Results: In SAD cohorts, 25 patients received rhFGF18; 8 received
placebo. In MAD cohorts, 30 patients received rhFGF18; 10 received
placebo. Age range 48.5–87.1 y; BMI range 21.1–46.8 kg/m2. No
local/systemic acute safety concerns emerged, no subjects discontinued
treatment prematurely, no adverse events (AE) led to discontinuation.
Two deaths were reported: 1 patient (MAD 30mg) died of pulmonary
embolism 2 days after TKR surgery (considered likely to be unrelated to
study drug); 1 patient (MAD placebo) died from myocardial infarction
3 months after his last dose of study drug (considered unrelated
to study drug). No pattern was evident among the 8 other serious
AE (all considered unrelated to study drug). Acute inﬂammatory
reactions were slightly more common in 300mg rhFGF18-treated groups.
Treatment emergent AE did not increase in treatment vs. placebo groups.
No systemic exposure to rhFGF18 or antibodies against FGF18 were
detected. Systemic biomarkers of cartilage and bone metabolism, and
inﬂammation, showed no systemic effect of rhFGF18. Although the study
was not designed to demonstrate efﬁcacy, cartilage samples obtained
during TKR surgery suggested chondrocyte proliferation, improved
histological grading and improvement in biomechanical properties after
rhFGF18. In the 30 patients evaluated with MRI there was a suggestion
of increased cartilage volume, especially in the medial femorotibial
compartment. No changes were seen on X-ray. Improvement of OA
symptoms occurred in both placebo and rhFGF18-treated groups.
Conclusions: These Phase I results suggest no local or systemic acute
safety concerns with rhFGF18 i.a. single or multiple injections. The
proportion of patients experiencing ≥1 AE was not increased in rhFGF18
groups. No systemic exposure was detected after injection. Cartilage
samples obtained during TKR surgery suggest that rhFGF18 elicits an
anabolic response in late-stage OA. MRI ﬁndings showed a positive trend,
although longer observation with more patients is required to conﬁrm
drug effects. These results are encouraging for further investigation of
rhFGF18 as a potential DMOAD.
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IRON OVERLOAD AND HEMOCHROMATOSIS (HFE) MUTATION
CORRELATE WITH CLINICAL OUTCOMES IN AN OSTEOARTHRITIS
COHORT
L. Kennish1, M. Attur1, X. Huang1, Y. Lai2, C. Liu2, S. Krasnokutsky1,
J. Samuels1, S.B. Abramson1. 1NYUHosp. for Joint Diseases-Rheumatology,
New York, NY, USA; 2NYUHosp. for Joint Diseases-Orthopedics, New York,
NY, USA
Purpose: Iron may be a contributing risk factor for osteoarthritis (OA)
development – increased iron is found in OA synovial ﬂuid and is
cytotoxic towards chondrocytes. Additionally, patients with hereditary
hemochromatosis develop an OA phenotype that is associated with
higher ferritin levels. We examined the hypothesis that serum ferritin
is elevated in patients with knee OA and that levels of ferritin correlate
with OA severity.
Methods: The study included 150 patients with symptomatic knee OA
(patients were diagnosed by ACR criteria with a WOMAC score >125)
and 21 controls who were enrolled in a 2 year longitudinal study.
Exclusion criteria were steroid use, inﬂammatory arthritis, infection,
diabetes, hepatic/renal disease, or heart failure. Baseline clinical (age,
gender, BMI, WOMAC pain score) and radiographic characteristics (KL
score) were obtained. Cross sectional peripheral blood samples were
analyzed for serum ferritin by ELISA. Plasma PGE2 and COMP fragments
were measured by ELISA and PCR based HFE genotyping performed on
patients and controls. Statistical analysis included ANOVA and student’s
t-test.
Results: Ferritin was measured in 129 OA patients with mean age
65 years (35% men), BMI 26.5 and, in those who had radiographic scoring,
KL score 0–2 (48) and 3–4 (48), and 20 controls with mean age 56 years
(55% men), and BMI 26.5. Men and women with OA had higher average
ferritin than those without OA (one way ANOVA, p =0.008; men: 71.06
vs. 40.42ng/ml, p = 0.01; women: 42.57 vs. 32.98ng/ml, p=ns). Ferritin
levels greater than 100ng/ml were observed in 13% of patients with OA,
and in 0% of controls. OA patients had higher frequency of homozygous
HFE gene mutation C282Y/C282Y (2.29%) compared to controls (0%)
and published controls (0.26%, z=3.2). Higher ferritin levels positively
correlated with worsening KL scores in the total OA population (KL
0–2: 38.28 vs. KL 3–4: 62ng/ml, p = 0.02) and in men with OA (KL
0–2 45.03 vs. KL 2–4: 91.69ng/ml, p = 0.04). Also associated with higher
ferritin were increasing age, BMI, and WOMAC pain scores and the
HFE C282Y/C282Y mutation. PGE2 was elevated in OA patients (160.2
vs. 69.3 ng/ml, p < 0.001) and in those with higher ferritin (p = 0.05).
Similarly, COMP fragments was also elevated in OA patients (286.7 vs.
109.9 ng/ml, p = 0.03) and in those with higher ferritin (p = 0.05).
Conclusions: Selected patients with symptomatic knee OA have
increased ferritin compared to controls, as well as an increased incidence
of the C282Y/C282Y HFE gene mutation. Higher levels of ferritin in OA are
